Medication costs following subthalamic nucleus deep brain stimulation for Parkinson's disease

Movement Disorders

Volumn 29, Issue 2, 2014, Pages 275-276

  Toft, Mathias ^a   Dietrichs, Espen ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENTS; COST OF ILLNESS; DEEP BRAIN STIMULATION; FEMALE; HUMANS; MALE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SUBTHALAMIC NUCLEUS;

EID: 84894225035     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25504     Document Type: Letter

References (5)

1. Weaver FM, Stroupe KT, Cao L, et al. Parkinson's disease medication use and costs following deep brain stimulation. Mov Disord 2012;27:1398-1403.
2. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-2091.
3. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(Suppl 14):S290-S304.
4. Toft M, Lilleeng B, Ramm-Pettersen J, et al. Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation. Mov Disord 2011;26:1931-1934.
5. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-671.